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osting by EAbstract On November 18, 2011, the US Food and Drug Administration (US FDA) announced
that breast cancer indication for Avastin (bevacizumab) had been withdrawn after concluding that
the drug has not been shown to be safe and effective for the treatment of breast cancer. The speciﬁc
indication that was withdrawn was for the use of bevacizumab in metastatic breast cancer, with
paclitaxel for the treatment of patients who have not received chemotherapy for metastatic
HER2-negative breast cancer.
The US FDAs decision has been met with emotion and confusion among the public and health
professionals. The purpose of this article is to review the regulatory history of bevacizumab for
breast cancer and to examine the scientiﬁc evidence that led to the approval and subsequent with-
drawal of this indication. Bevacizumab also provides the opportunity to illustrate the value of free
publicly available US FDA reviews that may contain rigorously reviewed unpublished data and
analyses and to contrast the decisions made in the US and Europe about bevacizumab and breast
cancer.
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lsevier1. Introduction
On November 18, 2011, US FDA Commissioner Margaret
Hamburg announced that her agency was revoking breast can-
cer indication for Avastin (bevacizumab) after concluding that
the drug has not been shown to be safe and effective for the
treatment of breast cancer. The speciﬁc indication that was re-
voked was for the use of bevacizumab in metastatic breast can-
cer, with paclitaxel for treatment of patients who have not
received chemotherapy for metastatic HER2-negative breast
cancer (US Food and Drug, 2011).
The US FDAs ﬁnal decision to remove bevacizumab breast
cancer indication has been met with emotion and confusion
among public and health professionals. The purpose of this
article is to review the regulatory history of bevacizumab for
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the approval and withdrawal of this indication. The bev-
acizumab case also provides the opportunity to illustrate the
value of free publicly available US FDA reviews and to con-
trast different decisions made in the US and Europe about
Avastin and breast cancer.
Bevacizumab is now indicated for metastatic colorectal can-
cer, with IV 5 ﬂuorouracil based chemotherapy for ﬁrst or sec-
ond-line treatment; non-squamous non-small cell lung cancer,
with carboplatin and paclitaxel for ﬁrst-line treatment of unre-
sectable, locally advanced, recurrent or metastatic disease;
glioblastoma, as a single agent for adult patients with progres-
sive disease following prior therapy (no data are available
demonstrating improvement in disease related symptoms or
survival with Avastin); and metastatic renal cell carcinoma
with interferon.
Bevacizumab was ﬁrst approved in the US in February
2004 for the treatment of advanced colon cancer and has been
approved since for advanced lung (2006), kidney and brain
(glioblastoma) cancers (2009). Avastin was approved for met-
astatic breast cancer in 2008 under the US FDAs Accelerated
Approval Program. In 2010 worldwide sales of bevacizumab
were US$ 6.8 billion.
Under the Accelerated Approval Program regulations a
drug may be approved based on its effect on a biomarker or
surrogate endpoint such as tumor shrinkage that suggests the
drug has an important clinical beneﬁt for patients. However,
the regulations require additional clinical trials that conﬁrm
that there is a meaningful clinical beneﬁt to patients such as
increased survival.
While reading this article two facts are to be kept in
mind. First, bevacizumab is a drug with substantial toxicity.
The US FDA requires that Avastin display a Black Box
Warning in the drug’s professional product leaﬂet. A Black
Box Warning is the strongest type of safety alert that the
US FDA can require in a drug’s product leaﬂet (Genentech
Inc., 2011).
The second is that Accelerated Approval may be granted to
drugs to treat life threatening conditions for which there is no
effective therapy but there is preliminary evidence that the
drug might be effective. Most often this involves drugs for can-
cer, HIV/AIDS, and inhalation anthrax. By regulation it is the
responsibility of drug’s manufacturer to conﬁrm that the drug
actually provides a meaningful clinical beneﬁt such as in-
creased survival for patients .
Drugs such as bevacizumab that are granted Accelerated
Approval are also subject to Accelerated Withdrawal if the
required conﬁrmatory studies fail to verify a clinical beneﬁt
or the drug is not shown to be safe and effective.
As noted above bevacizumab was ﬁrst approved in the US
in February 2004. The following are the major events involved
in the Accelerated Approval and Withdrawal of breast cancer
indication for Avastin.
2. Oncologic Drugs Advisory Committee – December 5, 2007
The US FDA convened a meeting of its outside Oncologic
Drugs Advisory Committee (ODAC) to consider the Genen-
tech, Inc. application to market bevacizumab for use in combi-
nation with paclitaxel, for the treatment of patients who have
not received chemotherapy for their locally recurrent or meta-static, HER2-negative breast cancer (US Food and Drug,
2007a).
Study E2100 was presented to the Advisory Committee to
support the new breast cancer indication for Avastin. This
study was an open-label, randomized trial that enrolled 722
subjects who had not previously received chemotherapy for
their locally recurrent or metastatic breast cancer. The subjects
were randomized (1:1) to receive paclitaxel alone or paclitaxel
plus bevacizumab. The primary efﬁcacy endpoint used is pro-
gression free survival (PFS). More discussion of PFS appears
later in this article.
The secondary endpoints in study E2100 were overall sur-
vival, objective response rate, duration of objective response,
and quality of life (QOL). The study was sponsored by the
US National Cancer Institute (NCI) and conducted by the
Eastern Cooperative Oncology Group (ECOG).
The addition of bevacizumab to paclitaxel resulted in a
5.5-month increase in median PFS with no statistically signif-
icant improvement in overall survival based on the analysis by
independent reviewers. The tumor response rate was higher
with bevacizumab plus paclitaxel as compared to paclitaxel
alone, 48.9% versus 22.2%, respectively.
The results of study E2100 are summarized in Table 1.
The collection of adverse events was limited to US National
Cancer Institute (NCI) Common Toxicity Criteria (CTC)
grade 3-5 adverse events. There was a 20.2% increase in grade
3-5 toxicity in the bevacizumab plus paclitaxel arm over paclit-
axel alone. Bevacizumab’s major safety concerns are hyperten-
sion, thromboembolic events, left ventricular dysfunction,
myocardial infarction, gastrointestinal perforation and pro-
teinuria. Death attributed to study drug by the FDA was
1.7% (6/363) in the Avastin plus paclitaxel arm when com-
pared zero (0/348) with paclitaxel alone.
The E2100 trial results were published in the New England
Journal of Medicine on December 27, 2007. The conclusion
read: ‘‘Initial therapy of metastatic breast cancer with paclit-
axel plus bevacizumab prolongs progression-free survival,
but not overall survival, as compared with paclitaxel alone.’’
(Miller et al., 2007).
The Advisory Committee member voted 5 to 4 against rec-
ommending approval of Avastin for breast cancer (US Food
and Drug, 2007b).
3. Avastin’s approval formetastatic breast cancer – February 22,
2008
The US FDAs decision to allow accelerated bevacizumab in
the treatment of breast cancer was not based on evidence
showing the drug improved survival or QOL. Additionally,
there was imbalance in the number of deaths in the
bevacizumab paclitaxel and paclitaxel only arms of study
E2100 (US Food and Drug, 2007a).
The approval of Avastin was based on the drug’s effect in
study E2100 on PFS. PFS measures time between the time
when a subject starts taking the drug or treatment of interest,
in this case Avastin plus paclitaxel, or the control, paclitaxel
alone and either death, or evidence, from radiological assess-
ment the tumor size has increased. At the time of bev-
acizumab’s approval the evidence was a 5.5 month increase
in median PFS that was statistically signiﬁcant. Avastin’s effect
on PFS was the basis for the drug’s approval.
Table 1 Results of study E2100.
Study arm Median PFS (months) Median OS (months) ORR
E2100
Paclitaxel + Avastin 11.3 26.5 48.9%
Paclitaxel 5.8 24.8 22.2%
Between-arm diﬀerence 5.5 1.7 26.7%
Hazard ratio (95% CI) 0.48 (0.39–0.61) p< 0.0001 0.87 (0.72–1.05) p= 0.137 (18.4%, 35%) p< 0001
CI = conﬁdence interval; ORR= objective response rate; OS = overall survival; PFS = progression free survival.
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The Oncologic Drugs Advisory Committee was asked in July
2010 to make a recommendation to the US FDA on whether
or not the bevacizumab breast cancer indication should be
withdrawn (US Food and Drug, 2010a).
As a condition for bevacizumab’s Accelerated Approval the
drug’s manufacturer was required by regulation to submit data
from two ongoing, placebo-controlled trials (AVADO and
RIBBON 1) to provide veriﬁcation of the Avastin’s treatment
effect on PFS and to provide additional information on the ef-
fects of the drug on overall survival.
The ﬁrst, the AVADO trial was a double blind, placebo-
controlled, three-arm trial of docetaxel plus placebo, docetaxel
plus bevacizumab 7.5 mg/kg, and docetaxel plus bevacizumab
15 mg/kg. A total of 736 subjects with HER2-neu negative tu-
mors who had not received prior chemotherapy for metastatic
breast cancer were enrolled. The addition of bevacizumab
7.5 mg/kg to docetaxel resulted in 30% increase in PFS [HR
0.70 (95% CI 0.55, 0.90)] with an observed 0.8-month differ-
ence in median PFS while the addition of bevacizumab
15 mg/kg to docetaxel resulted in 39% increase in PFS [HR
0.62 (95% CI 0.48, 0.79)] with an observed 0.88-month differ-
ence in median PFS. Objective responses were observed in
44% of patients in the placebo arm, 55% in the Avastin
7.5 mg/kg arm (p-value 0.0295) and 63% in the Avastin
15 mg/kg arm (p-value 0.0001). Mature survival data showedTable 2 Summary of AVADO and RIBBON 1 results.
Study arm Median PFS (months)
AVADO
Docetaxel + Avastin 15 mg/kg 8.8
Docetaxel + Placebo 7.9
Between-arm diﬀerence 0.9
Hazard ratio (95% CI) 0.62 (0.48–0.79) p= 0.0003
Docetaxel + Avastin 7.5 mg/kg 8.7
Docetaxel + Placebo 7.9
Between-arm diﬀerence 0.8
Hazard ratio (95% CI) 0.70 (0.55–0.90) p= 0.0054
RIBBON 1
Taxene/Anthracycline + Avastin 9.2
Taxene/Anthracycline + Placebo 8.0
Between-arm diﬀerence 1.2
Hazard ratio (95% CI) 0.64 (0.52–0.80) p< 0.0001
Capecitabine + Avastin 8.6
Capecitabine + Placebo 5.7
Between-arm diﬀerence 2.9
Hazard ratio (95% CI) 0.69 (0.56–0.84) p= 0.0002
CI = conﬁdence interval; NR= not reached; ORR= objective responsean HR of 1.103 (95% CI 0.84, 1.45) favoring the placebo
arm over the 7.5 mg/kg Avastin arm. The HR for overall
survival was 1.003 (95% CI 0.76, 1.32) for the 15 mg/kg
bevacizumab arm compared to the placebo arm.
There was an absolute decrease in survival in both
bevacizumab arms of AVADO trial though these differences
were not statistically signiﬁcant.
In the AVADO trial there was an increase of NCI CTC
grade 3-5 adverse events, serious adverse events and study drug
discontinuation with the addition of Avastin to docetaxel.
More patients in the Avastin containing arms required inter-
ruption or dose reduction or discontinuation of docetaxel
due to an adverse event.
The second trial, the RIBBON 1 study was a double blind,
randomized, parallel group study conducted in women with
metastatic or locally recurrent HER2-neu negative adenocarci-
noma of the breast that had not received prior chemotherapy
for their advanced or metastatic cancer. A total of 1237 sub-
jects were randomized (2:1) to receive anthracycline- or tax-
ane-based chemotherapy (n= 622) or capecitabine (n= 615)
in combination with Avastin or placebo.
The addition of bevacizumab to taxane/anthracycline-
based chemotherapy resulted in 36% increase in PFS [HR
0.64 (95% CI 0.52, 0.80)], with an observed 1.2-month differ-
ence in median PFS. Objective response rate was higher in the
bevacizumab containing arm, with an absolute increase of
13.5% (95% CI 4.6, 22.3%) with the addition of Avastin toMedian OS (months) ORR
3.2 63.1%
31.9 44.4%
1.7 18.7%
1.00 (0.76–1.32) p= 0.98 (9.0%, 28.4%) p= 0.001
30.8 55.2%
31.9 44.4%
1.1 10.8%
1.10 (0.84–1.45) p= 0.48 (9.0%, 20.7%) p= 0.0295
27.5 51.3%
NR 37.9%
NR 13.5%
1.11 (0.86–1.43) p= 0.44 (4.6%, 22.3%) p= 0.0054
25.7 35.4%
22.8 23.6%
2.9 11.8%
0.88 (0.69–1.13) (3.4%, 26.2%) p= 0.0097
rate.
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analysis yielded an HR of 1.11 (95% CI 0.86, 1.43) favoring
the placebo arm.
The addition of bevacizumab to capecitabine resulted in a
31% increase in PFS [HR 0.69 (95% CI 0.56, 0.84)], with an
observed difference of 2.9 months in median PFS. Objective re-
sponse rate was higher in the Avastin containing arm, with an
absolute increase of 11.8% (95% CI 3.4, 20.2%) observed with
the addition of bevacizumab to capecitabine. A comparison of
the mature survival data for the capecitabine cohort showed an
HR of 0.88 (95% CI 0.69, 1.13) favoring the bevacizumab con-
taining arm.
Overall, the incidence of NCI CTC grade 3-5 adverse events
and serious adverse events were almost twice as high in the
bevacizumab arms compared to placebo arms in both cohorts.
The size of the improvement in PFS observed in the AVA-
DO and RIBBON 1 studies failed to conﬁrm the magnitude of
PFS improvement observed in the E2100 trial, the basis for
bevacizumab’s Accelerated Approval. The size of the treat-
ment effect is clinically important because it is a measure of
delaying symptoms from tumor progression, which has to be
weighed against the drug’s toxicity that is present for the dura-
tion of treatment. The addition of bevacizumab to chemother-
apy resulted in an increased rate of serious adverse events, in
NCI CTC grade 3-5 adverse events and of adverse events
attributable to bevacizumab in both studies. Overall survival
data showed hazard ratios favoring the placebo arms in both
the AVADO study and the taxane/anthracycline cohort of
the RIBBON 1 study.
Table 2 below summarizes the results of the AVADO and
RIBBON 1 studies.
The Oncology Drugs Advisory Committee voted Yes = 12;
No = 1; and Abstain = 0 to withdraw the metastatic breast
cancer indication for Avastin (US Food and Drug, 2010b).
5. Submission of AVADO and RIBBON 1 trials to the US FDA
and the US FDA brieﬁng documents
The importance of the US FDA free publicly available brieﬁng
documents is highlighted by the bevacizumab AVADO and
RIBBON 1 trials. US FDA brieﬁng documents are safety
and efﬁcacy analyses prepared by the agency for discussion
at public advisory committee meetings. The brieﬁng docu-
ments may contain rigorously conducted analyses of data sub-
mitted by a manufacturer that are never published or not
published in a timely manner.
The analyses of the AVADO and RIBBON 1 trials were
ﬁrst made available to the public before the July 10, 2010,
Oncologic Drugs Advisory Committee (US Food and Drug,
2010a).
The AVADO results were published online from the
European Journal of Cancer on July 15, 2011 (Pivot et al., 2011).
This is one year after the analyses were available on the US
FDA’s Web site and eight months after the agency announced
that it was beginning procedures to withdraw bevacizumab’s
breast cancer indication (US Food and Drug, 2010c). The
authors of the European Journal of Cancer paper concluded:
In this exploratory sub-analysis in AVADO, bevacizumab
plus docetaxel showed efﬁcacy in elderly patients similar
to the overall study population. There were no unexpected
safety signals in patients aged 65 years or older.This sub-analysis was not pre-speciﬁed and gives an impres-
sion of the safety and efﬁcacy of Avastin that may be inter-
preted as quite different from the analyses presented in the
US FDA brieﬁng documents.
RIBBON 1was published in the Journal of Clinical Oncology
on April 1, 2010 (Robert et al., 2011). This was 10 months after
the posting of the RIBBON 1 analyses on the US FDA’s Web
site. And this was four months after the US FDA had begun
the regulatory procedures to remove bevacizumab’s breast can-
cer indication (US Food and Drug, 2010c).
The authors of the published RIBBON 1 study concluded:
These data, together with those from E2100 and AVADO,
provide a clear rationale for adding BC [bevacizumab] to
ﬁrst-line cytotoxic therapy for patients with HER2-negative
MBC [metastatic breast cancer].
Accessing publicly available US FDA brieﬁng documents
provide analyses that may not be published that may lead
to different conclusions of the therapeutic value of a drug
than conclusions that rely only on the published medical
literature.
6. European Medicines Agency (EMEA) and Avastin for breast
cancer
The bevacizumab breast cancer indication remains in Europe.
The EMEA issued the following statement in December 2010.
For Avastin in combination with paclitaxel, the Committee
concluded that the beneﬁts continue to outweigh the risks,
because the available data have convincingly shown to pro-
long progression-free survival of breast cancer patients
without a negative effect on the overall survival (European
Medicines, 2011).
The US FDA and EMEA have reached different scientiﬁc
conclusions on the efﬁcacy and safety of drugs in the past.
There is an agreement between bevacizumab’s manufacturer,
the US FDA that there is no beneﬁt in survival or QOL with
the bevacizumab paclitaxel combination for breast cancer
(US Food and Drug, 2011).
The reasons for different decisions are not readily apparent
between the US FDA and EMEA. There is a lack of transpar-
ency in EMEA that must be contrasted with the US FDA’s
publicly available reviews of bevacizumab.
Each country’s national drug regulatory authority must
reach its own decisions based on its own regulations to ap-
prove or withdraw approval of a drug or a drug’s speciﬁc indi-
cations. In developing and emerging countries accessing free
publicly available reviews may allow an independent analysis
of the therapeutic value of the drug that is not possible by rely-
ing solely on the published medical literature including clinical
practice guidelines, review articles, and electronic databases.
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